Silo Pharma Announced An Update On Its Dosage And Time-Release Ketamine-Loaded Implant, Designated As SP-26, Which Is Being Developed As A Potential At-Home Pain Relief Treatment For Fibromyalgia And Other Chronic Pain Conditions
Portfolio Pulse from Benzinga Newsdesk
Silo Pharma has provided an update on the development of SP-26, a ketamine-loaded implant for at-home pain relief treatment for fibromyalgia and other chronic pain conditions. The company is working with Sever Pharma Solutions to advance SP-26 through analytical testing and small batch pre-clinical proof of concept extrusion trials to assess drug release and stability.
December 28, 2023 | 1:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Silo Pharma's SP-26, a ketamine-loaded implant for chronic pain, is advancing in development with Sever Pharma Solutions, potentially boosting investor confidence in the company's pipeline.
The positive update on SP-26's development could lead to increased investor optimism about Silo Pharma's product pipeline and its potential market impact, especially for at-home pain relief treatments. This news may drive short-term interest and investment in SILO, as it demonstrates progress in a novel therapeutic area.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100